文献速递手外科与足踝外科

双柄硅胶假体置换术治疗终末期僵硬拇的疗效分析

Silastic first metatarsophalangeal joint arthroplasty for the treatment of end-stage hallux rigidus.
PubMed 文献 · Bone Joint J · 2020-01-01

回顾性分析108例(76例患者)双柄硅胶假体置换治疗终末期僵硬拇,平均随访5.3年,假体生存率97.2%,MOXFQ从78.1改善至11.0,VAS疼痛从7/10降至1.3/10,满意度90.6%。翻修率2.8%,作者认为该假体可作为关节融合的可靠替代方案。

要点

  • 双柄硅胶假体置换治疗终末期僵硬拇平均随访5.3年生存率97.2%。
  • 翻修率2.8%,因感染1例、柄断裂2例(术后10.4年和13.3年)。
  • 患者报告结局和疼痛显著改善,满意度达90.6%。

核心结论

  • 双柄硅胶假体置换术在平均5.3年随访中假体生存率97.2%,未发现进行性骨溶解,可作为终末期僵硬拇关节融合的可靠替代方案。

主要发现

  • 平均随访5.3年(2.1至14.1年)时假体生存率为97.2%。
  • MOXFQ评分从78.1改善至11.0,VAS疼痛评分从7/10降至1.3/10。
  • 满意度为90.6%,3个植入物(2.8%)需翻修,其中1例术后1个月因感染、2例分别于术后10.4年和13.3年因柄断裂。
  • 非翻修的再手术率为1.9%,23.1%的患者出现轻微并发症,21.1%的患者影像学显示非进行性无症状囊肿。

关键数值与推荐

  • 原文提及关节融合术的金标准地位及其并发症发生率:骨不连高达10%、再手术14%、跖骨痛10%。

临床怎么用

  • 对于终末期僵硬拇患者,双柄硅胶假体置换可提供与关节融合相当的预后,可作为手术替代选择之一。

局限性

  • 本研究为回顾性设计,缺乏与关节融合术的对照比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Arthroplasty for end-stage hallux rigidus (HR) is controversial. Arthrodesis remains the gold standard for surgical treatment, although is not without its complications, with rates of up to 10% for nonunion, 14% for reoperation and 10% for metatarsalgia. The aim of this study was to analyze the outcome of a double-stemmed silastic implant (Wright-Medical, Memphis, Tennessee, USA) for patients with end-stage HR. METHODS: We conducted a retrospective review of 108 consecutive implants in 76 patients, between January 2005 and December 2016, with a minimum follow-up of two years. The mean age of the patients at the time of surgery was 61.6 years (42 to 84). There were 104 females and four males. Clinical, radiological, patient reported outcome measures (PROMS) data, a visual analogue score (VAS) for pain, and satisfaction scores were collected. RESULTS: The survivorship at a mean follow-up of 5.3 years (2.1 to 14.1) was 97.2%. The mean Manchester Oxford Foot and Ankle Questionnaire (MOXFQ) scores improved from 78.1 to 11.0, and VAS scores for pain from 7/10 to 1.3/10. The rate of satisfaction was 90.6%. Three implants (2.8%) required revision; one for infection, one-month postoperatively, and two for stem breakage at 10.4 and 13.3 years postoperatively. There was a 1.9% reoperation rate other than revision, 23.1% of patients developed a minor complication, and 21.1% of patients had non-progressive and asymptomatic cysts on radiological review. CONCLUSION: We report a 97.2% survivorship at a mean follow-up of 5.3 years with this implant. We did not find progressive osteolysis, as has been previously reported. These results suggest that this double-stemmed silastic implant provides a predictable and reliable alternative with comparable outcomes to arthrodesis for the treatment of end-stage HR. Cite this article: Bone Joint J 2020;102-B(2):220-226.

来源:Bone Joint J,查看原文。版权归原作者所有。

引用

  1. Clough TM, Ring J. Silastic first metatarsophalangeal joint arthroplasty for the treatment of end-stage hallux rigidus. Bone Joint J. 2020. PMID: 32009425. doi:10.1302/0301-620X.102B2.BJJ-2019-0518.R2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。